Clinical trials: Epilepsy, Motor Partial
Epilepsies, Partial
Post-Authorization Safety Study to Assess the Safety of Vimpat as add-on Therapy in Patients With Partial-onset Seizures
SP942 is a non-interventional post-authorization safety study (PASS) to evaluate the long-term safety and tolerability of Vimpat® (Lacosamide, LCM) as add-on treatment in patients with Epilepsy 16 years and older with…
- Trial name
- PASS (NCT00771927)
- Testing
- Lacosamide
- Where
- 62 sites in France, Germany and 3 more
- Volunteers
- 1,005 people
- Sponsor
- UCB Pharma